How were American Renal Associates' earnings last quarter?

American Renal Associates Holdings, Inc. (NYSE:ARA) posted its quarterly earnings data on Wednesday, November, 11th. The company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.06 by $0.09. The business earned $209.69 million during the quarter, compared to analyst estimates of $211.50 million. American Renal Associates had a negative net margin of 2.04% and a negative trailing twelve-month return on equity of 3.56%.

What is Joseph Carlucci's approval rating as American Renal Associates' CEO?

62 employees have rated American Renal Associates Chief Executive Officer Joseph Carlucci on Glassdoor.com . Joseph Carlucci has an approval rating of 57% among the company's employees. This puts Joseph Carlucci in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of American Renal Associates own?

Based on aggregate information from My MarketBeat watchlists, some companies that other American Renal Associates investors own include Zevra Therapeutics (KMPH) , Exelixis (EXEL) , Amicus Therapeutics (FOLD) , Madrigal Pharmaceuticals (MDGL) , Mylan (MYL) , Spectrum Pharmaceuticals (SPPI) , Akorn (AKRX) , Fate Therapeutics (FATE) , Karyopharm Therapeutics (KPTI) and Kura Oncology (KURA) .

When did American Renal Associates IPO?

American Renal Associates (ARA) raised $161 million in an initial public offering (IPO) on Thursday, April 21st 2016. The company issued 7,500,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Barclays and Goldman Sachs served as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

NYSE:ARA

American Renal Associates (ARA) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free ARA Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $11.33
▼
$11.52
50-Day Range: $11.46
▼
$11.52
52-Week Range: $5.57
▼
$11.98

Volume: 9,831 shs
Average Volume: 106,940 shs
Market Capitalization: $397.94 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get American Renal Associates alerts:

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About American Renal Associates Stock (NYSE:ARA)

American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of December 31, 2019, it operated 246 dialysis clinics in partnership with 400 nephrologist partners treating approximately 17,300 patients in 27 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

Click for my No. 1 investment, all free of charge, click here.

ARA Stock News Headlines

August 31, 2023 | benzinga.com

Bayer's Kerendia® (finerenone) Included in Latest Focused Guideline Clinical Updates from European Society of Cardiology

February 22, 2023 | finance.yahoo.com

Anemia in Chronic Kidney Disease (Renal Anemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

January 11, 2023 | finance.yahoo.com

Liberation From Renal Replacement Therapy and Early Initiation to Be Supported by The Kidney Function Biomarker Proenkephalin A 119-159 (penKid)

January 2, 2023 | finance.yahoo.com

Continuous Renal Replacement Therapy Global Market Report 2022: Rising Prevalence of Acute Kidney Injuries Drives Demand

October 7, 2022 | bbc.com

Dalian Atkinson: Footballer killed hours before renal treatment

June 22, 2022 | finance.yahoo.com

ARA Appoints James Myers Vice President, Program Innovation and Growth

June 20, 2022 | thestreet.com

American Renal Associates Holdings, Inc. News

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

December 6, 2021 | markets.businessinsider.com

SEC Charges Dialysis Provider and Three Former Senior Executives with Revenue Manipulation Scheme

December 6, 2021 | law360.com

SEC Hits Dialysis Co., Execs With Accounting Fraud Claim

December 6, 2021 | nasdaq.com

U.S. SEC charges dialysis provider, three former executives with revenue manipulation

October 21, 2021 | sg.finance.yahoo.com

Strive Health Unveils Strive Care Partners, Reaches 500 Nephrology Partners

October 19, 2021 | investing.com

American Renal Associates Holdings Inc (ARA)

See More Headlines

Receive ARA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for American Renal Associates and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/11/2020
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Miscellaneous Health & Allied Services
Sub-Industry: N/A
Current Symbol: NYSE:ARA
CUSIP: N/A
CIK: 1498068
Web: www.americanrenal.com
Phone: 978-922-3080
Fax: N/A
Employees: 4,977
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): $0.26
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-13,790,000.00
Net Margins: -2.04%
Pretax Margin: N/A
Return on Equity: -3.56%
Return on Assets: -0.24%

Debt

Debt-to-Equity Ratio: 7.54
Current Ratio: 1.05
Quick Ratio: 1.02

Sales & Book Value

Annual Sales: $822.52 million
Price / Sales: 0.48
Cash Flow: $1.69 per share
Price / Cash Flow: 6.80
Book Value: $2.59 per share
Price / Book: 4.45

Miscellaneous

Outstanding Shares: 34,543,000
Free Float: N/A
Market Cap: $397.94 million
Optionable: Optionable
Beta: 1.11

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Joseph A. Carlucci (Age 66)
Co-Founder, CEO & Chairman
Comp: $1.06M
Mr. Syed T. Kamal (Age 67)
Co-Founder, Pres & Director
Comp: $947.14k
Dr. Don E. Williamson (Age 58)
Exec. VP & COO
Comp: $1.22M
Mr. Mark C. Herbers (Age 65)
Interim CFO & Interim Chief Accounting Officer
Mr. Richard Pacheco CFE
AVA, MBA, VP of Admin.
Mr. Neal Minahan
Chief Compliance Officer & VP
Ms. Victoria A. Labriola Esq.
M.B.A., VP, Gen. Counsel & Sec.
Ms. Jennifer Hood
VP of HR
Dr. Richard Cronin M.D.
Chief Medical Officer
Ms. Shari Cousins R.N.
C.N.N., Sr. VP of Clinical & Regulatory Services

Key Competitors

View All Competitors

ARA Stock Analysis - Frequently Asked Questions

How were American Renal Associates' earnings last quarter?: American Renal Associates Holdings, Inc. (NYSE:ARA) posted its quarterly earnings data on Wednesday, November, 11th. The company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.06 by $0.09. The business earned $209.69 million during the quarter, compared to analyst estimates of $211.50 million. American Renal Associates had a negative net margin of 2.04% and a negative trailing twelve-month return on equity of 3.56%.
What is Joseph Carlucci's approval rating as American Renal Associates' CEO?: 62 employees have rated American Renal Associates Chief Executive Officer Joseph Carlucci on Glassdoor.com. Joseph Carlucci has an approval rating of 57% among the company's employees. This puts Joseph Carlucci in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of American Renal Associates own?: Based on aggregate information from My MarketBeat watchlists, some companies that other American Renal Associates investors own include Zevra Therapeutics (KMPH), Exelixis (EXEL), Amicus Therapeutics (FOLD), Madrigal Pharmaceuticals (MDGL), Mylan (MYL), Spectrum Pharmaceuticals (SPPI), Akorn (AKRX), Fate Therapeutics (FATE), Karyopharm Therapeutics (KPTI) and Kura Oncology (KURA).
When did American Renal Associates IPO?: American Renal Associates (ARA) raised $161 million in an initial public offering (IPO) on Thursday, April 21st 2016. The company issued 7,500,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Barclays and Goldman Sachs served as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

This page (NYSE:ARA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

American Renal Associates (ARA) Stock Price, News & Analysis

About American Renal Associates Stock (NYSE:ARA)

ARA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

ARA Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info